Immunome entered into a definitive agreement to acquire Ayala’s lead assets including AL102 for the treatment of Desmoid Tumors and related drug candidate AL101
Under the terms of the agreement, Ayala will receive a payment of $20M in cash and $30M in Immunome common stock at the closing of the transaction at a 30-day VWAP as of Feb 1, 2024 along with development and commercial milestone payments of $37.5M
AL102, a small molecule gamma secretase inhibitor, is currently being evaluated in a P-III (RINGSIDE) clinical trial in comparison with Ogsiveo (nirogacestat) among patients with desmoid tumors. Later in Nov 2023, the US FDA approved AL102 based on the results depicting clinically meaningful anti-tumor activity across multiple parameters
Ref: Immunome | Image: Ayala
Related News:- Ayala Pharmaceuticals Reports First Patient Dosing of AL102 in P-III (RINGSIDE) trial for the Treatment of Desmoid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
